OP-724-002 study

INTERVENTION: CBP/beta‐catenin inhibitor Cohort A (HCV, HBV) : ‐ foscenvivint iv. twice a week ‐ foscenvivint iv. once a week and placebo iv. once a week ‐ Placebo iv. twice a week Cohort B (NASH) : ‐ foscenvivint iv. twice a week ‐ Placebo iv. twice a week Administration period: 24weeks, Observation period: 52weeks D060449 CONDITION: D008103 Decompensated cirrhosis related with HCV, HBV or NASH ; Decompensated cirrhosis, HCV, HBV, NASH Decompensated cirrhosis, HCV, HBV, NASH PRIMARY OUTCOME: Child‐Pugh score SECONDARY OUTCOME: Child‐Pugh score, ALBI score, Liver stiffness, Serum fibrosis markers, etc. INCLUSION CRITERIA: 1. Patients with decompansated cirrhosis (Child‐Pugh class B: Score 7‐9) 2. Patients with liver cirrhosis related with HCV, HBV, or NASH 3. Patients with performance Status: 0‐2 4. Patients with serum albumin levels =<3.5 g/dL